Biologics Prior Auth for Dermatology: A Complete Practice Guide

Dermatology practices submit more biologic prior authorizations per condition type than almost any other specialty. Plaque psoriasis alone involves a formulary of more than a dozen approved biologics across four mechanism classes. Atopic dermatitis has added dupilumab and newer IL-31 and IL-13 inhibitors. Hidradenitis suppurativa, once underserved by biologic options, now has multiple approved agents with complex, condition-specific PA requirements.

The challenge isn't knowing which drug to prescribe — that's a clinical decision. The challenge is knowing what each payer needs to see, for each condition, to approve each drug on the first submission. This guide breaks it down by condition.

Plaque Psoriasis

Psoriasis is the highest-volume biologic PA in most dermatology practices, and the documentation requirements are the most standardized of the three major conditions covered here. That standardization is a double-edged sword: payer criteria are relatively consistent, but reviewers apply them precisely.

Severity Documentation: BSA and PASI

Almost every commercial payer and Medicare plan requires documentation of moderate-to-severe psoriasis before authorizing a biologic. The quantitative thresholds vary slightly, but the standard framework uses two measures:

Body Surface Area (BSA): Most payers define moderate disease as BSA ≥ 10%. Some plans use 5% as the threshold for palms, soles, genitals, or face involvement (high-impact areas), where functional impairment at lower BSA can justify biologic approval
PASI (Psoriasis Area and Severity Index): Moderate-to-severe typically defined as PASI ≥ 12, though some payers accept PASI ≥ 10. A few payers also reference DLQI (Dermatology Life Quality Index) ≥ 10 as a qualifying severity measure

Both scores need to be documented in the visit note, not just referenced in the PA letter. A payer reviewer will want to see that the scores were actually captured at a recent visit — not calculated retroactively from a description of the patient's disease.

Step Therapy: Phototherapy and Conventional Systemics

Most commercial payers require a step therapy sequence before authorizing a biologic for psoriasis. The typical sequence runs:

Topical therapies (high-potency corticosteroids, vitamin D analogues, tazarotene) for mild-to-moderate disease — documented failure or inadequate control for BSA/PASI qualifying for biologic consideration
Phototherapy (narrowband UVB is preferred; PUVA accepted) — minimum 12 to 36 sessions at most plans, or documented contraindication (photosensitizing medications, history of skin cancer, inability to travel for treatment, access limitations)
Conventional systemic (methotrexate, acitretin, or cyclosporine) — minimum 3 months at adequate dose, or documented intolerance or contraindication

The phototherapy step is where practices most often stumble. Access to phototherapy is genuinely limited in many areas, and insurance coverage for it is inconsistent. Many patients can't practically complete a phototherapy course — but "patient didn't do phototherapy" is not a documented exception. The exception needs to say why: nearest phototherapy center is 90 minutes away, patient works full-time and cannot attend three times weekly, patient has a documented photosensitizing condition or medication.

Biologic Sequence for Psoriasis

Once the step therapy box is checked, the biologic choices span four mechanism classes:

TNF inhibitors: Adalimumab, etanercept (and biosimilars) — the oldest options, now often non-preferred at many payers
IL-12/23 inhibitor: Ustekinumab (Stelara) — still widely covered, quarterly dosing is an adherence advantage
IL-17 inhibitors: Secukinumab (Cosentyx), ixekizumab (Taltz), bimekizumab (Bimzelx) — preferred tier at many commercial plans for moderate-to-severe psoriasis
IL-23 inhibitors: Risankizumab (Skyrizi), guselkumab (Tremfya), tildrakizumab (Ilumya) — among the highest PASI 90/100 response rates in trials, increasingly formulary-preferred

When a payer requires a specific biologic as a first-line option within the biologic step, that requirement needs to appear in your documentation. If Cigna requires a TNF inhibitor trial before authorizing an IL-17 inhibitor, document the TNF trial history explicitly.

Psoriasis PA Documentation Checklist

Current BSA percentage (documented in visit note within 90 days)
Current PASI score (same)
DLQI if payer policy references it
Topical therapy history: agents used, duration, documented inadequate control
Phototherapy history or documented exception with specific reason
Conventional systemic history: drug, dose, duration, reason for discontinuation
Specific ICD-10: L40.0 (plaque psoriasis), not L40.9 (unspecified)
If PsA is concurrent: separate M07.xx codes and rheumatology coordination

Atopic Dermatitis

Dupilumab (Dupixent) transformed atopic dermatitis treatment when it launched in 2017. By 2026, the AD biologic landscape has expanded to include tralokinumab (Adbry), lebrikizumab (Ebglyss), and the IL-31 inhibitor nemolizumab (Nemluvio), with additional agents in late-stage development. Each has condition-specific PA requirements, and dupilumab's market position means it carries the most developed payer coverage criteria.

Severity Scoring: EASI and IGA

The Eczema Area and Severity Index (EASI) is the primary quantitative tool payers reference for AD severity documentation. Most payers require EASI ≥ 16 (moderate-to-severe) for biologic authorization, though some accept IGA (Investigator's Global Assessment) score of ≥ 3 as an alternative.

EASI documentation must appear in the treating clinician's notes — not just referenced in the PA letter. Practices that don't routinely capture EASI at visits often face initial denials for this reason alone, even when the patient's disease clearly qualifies clinically. Getting into the habit of documenting EASI at every AD visit where biologic therapy is under consideration is the single most impactful workflow change most dermatology practices can make.

Step Therapy for AD

For dupilumab specifically, the FDA-approved label covers moderate-to-severe AD inadequately controlled by topical therapy. Payer criteria for the topical therapy failure step vary:

Most commercial payers: Require documented failure of at least two topical therapies — typically a high-potency corticosteroid plus either a topical calcineurin inhibitor (tacrolimus, pimecrolimus) or crisaborole (Eucrisa). Some plans require dupilumab trial before authorizing newer agents like tralokinumab or lebrikizumab
Medicare: Coverage under LCD framework — check your MAC's specific LCD for dupilumab, as criteria vary by jurisdiction
Pediatric patients: Dupilumab is approved down to 6 months for AD. Pediatric PA requirements are generally similar to adult criteria but may have age-specific IGA or EASI thresholds

For tralokinumab and lebrikizumab, expect most payers to require a dupilumab trial and failure before authorizing these agents in 2026. The "dupilumab-inadequate response" documentation requirement parallels the DMARD-step requirements in RA — you need dose, duration, and objective evidence of inadequate response or adverse event.

Atopic Dermatitis PA Documentation Checklist

Current EASI score or IGA score ≥ 3 (documented in visit note)
Percentage BSA affected (many payers use this alongside EASI)
Topical therapy history: corticosteroid class used, duration, documented inadequate control
Topical calcineurin inhibitor or PDE-4 inhibitor trial history
For tralokinumab/lebrikizumab: dupilumab trial history with documented response failure or adverse event
ICD-10: L20.9 (atopic dermatitis, unspecified) — verify payer accepts this vs. L20.89
Age documentation for pediatric patients

Hidradenitis Suppurativa

HS is the condition where PA documentation complexity is highest relative to the biologic options available. Adalimumab (Humira and biosimilars) remains the most-approved biologic for HS, with secukinumab (Cosentyx) receiving FDA approval for HS in 2023 and additional agents in the pipeline. Payer coverage for HS biologics is less consistent than for psoriasis or AD — and the documentation requirements reflect that inconsistency.

Hurley Staging: The Required Severity Framework

Hurley staging is to HS what PASI is to psoriasis — the severity classification framework that payers have built their coverage criteria around. Most commercial payers require Hurley Stage II or III for biologic authorization:

Hurley Stage I: Abscess formation, single or multiple, without sinus tracts or scarring — typically not covered for biologics
Hurley Stage II: Recurrent abscesses with sinus tract formation and scarring, single or multiple widely separated lesions — meets criteria for most biologic PA approvals
Hurley Stage III: Diffuse or near-diffuse involvement or multiple interconnected sinus tracts and abscesses — clear biologic indication

The Hurley stage must be documented in the clinical note. A general description of "severe HS with multiple abscesses and sinus tracts" may accurately describe Stage III disease, but if the note doesn't say "Hurley Stage III," some reviewers will mark the severity criterion as unmet.

Prior Treatment for HS

Antibiotic therapy is the primary step therapy requirement for HS biologics. Most payers require documentation of:

Oral antibiotic trial — typically tetracycline class (doxycycline 100mg BID is the standard reference) for minimum 3 months
Combination antibiotic therapy (clindamycin + rifampin) at plans that require two antibiotic steps
Documented inadequate response: ongoing flares, new lesion formation, or progression of sinus tract disease despite antibiotics

HS documentation also benefits from photographic records. Many payers for HS biologics specifically note that clinical photographs documenting active disease and sinus tract involvement strengthen the submission. If your practice photographs HS patients routinely, reference the photographic documentation in the PA letter.

Secukinumab for HS: Newer Coverage Considerations

Secukinumab's HS approval is more recent than adalimumab's, and payer coverage policies are still catching up. Some plans have coverage criteria for secukinumab in HS that were initially written for psoriasis and imperfectly adapted. When submitting secukinumab for HS, verify the payer's specific HS policy — not the general secukinumab policy — and address both the HS severity criteria and any biologic sequencing requirements (some plans require adalimumab trial and failure before authorizing secukinumab for HS).

HS PA Documentation Checklist

Hurley Stage documented explicitly (II or III)
Number of anatomic regions involved
Active lesion count and sinus tract documentation
Reference to photographic documentation if available
Antibiotic trial history: drug, dose, duration, response
Second antibiotic or combination trial if payer requires two-step antibiotic history
For secukinumab: adalimumab trial history if payer requires biologic sequencing
ICD-10: L73.2 (hidradenitis suppurativa)

How Luma Supports Dermatology PA Workflows

Dermatology is one of the highest-volume specialties for biologic PA submissions, and the condition-specific documentation requirements make it one of the most time-intensive. Psoriasis, AD, and HS each have different scoring tools, different step therapy sequences, and different payer-specific variants of those requirements.

Luma handles dermatology-specific biologic PAs by researching the current payer policy for the specific drug and indication, identifying which severity scores and prior treatment criteria the reviewer will be checking, and generating documentation that addresses each criterion explicitly. The platform covers the full dermatology biologic formulary — secukinumab, ixekizumab, dupilumab, adalimumab, risankizumab, and others — with condition-specific templates that adapt to payer requirements. You can see the broader approach to biologic documentation on the Luma blog.

The American Academy of Dermatology's prior authorization resources document what the specialty already knows: biologic PA is among the most burdensome administrative processes in dermatology practice, and the burden falls disproportionately on the staff managing documentation rather than on the clinical decision itself. Getting condition-specific documentation right the first time is the most direct lever available.

Sources:
1. American Academy of Dermatology — Prior Authorization Resources — aad.org
2. FDA — Dupilumab (Dupixent) Prescribing Information — fda.gov
3. National Psoriasis Foundation — PASI and BSA Scoring in Psoriasis — psoriasis.org
4. HS Foundation — Hurley Staging and Disease Assessment — hs-foundation.org
5. Journal of the American Academy of Dermatology — Biologic Treatment Guidelines — jaad.org